Literature DB >> 34033729

Prevalence and predictive factors of difficult-to-treat rheumatoid arthritis: the KURAMA cohort.

Ryu Watanabe1, Motomu Hashimoto1, Koichi Murata1,2, Kosaku Murakami3, Masao Tanaka1, Koichiro Ohmura3, Hiromu Ito1,2, Shuichi Matsuda2.   

Abstract

Difficult-to-treat rheumatoid arthritis (D2T RA) is a multifactorial condition in which disease activity of RA persists despite consecutive treatment with biological or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs). To evaluate the prevalence and predictive risk factors of D2T RA in our institution, a single-center, retrospective study was conducted. Medical records of RA patients, who visited our hospital from 2011 to 2020 and had a follow-up of more than 6 months, were retrospectively reviewed. D2T RA was defined as RA with a disease activity score of 28 - erythrocyte sedimentation rate (DAS28-ESR) of 3.2 or higher at the last visit, despite the use of at least two b/tsDMARDs. A logistic regression model was used to identify risk factors. A total of 672 patients were enrolled. The mean age at disease onset was 52.1 years and females were dominant (76.3%). After a mean follow-up of 46.6 months, patients with D2T RA accounted for 7.9% of overall patients. Multivariate analysis identified high rheumatoid factor (RF) levels (≥156.4 IU/mL, odds ratio [OR]: 1.95), DAS28-ESR (OR: 1.24), and coexisting pulmonary disease (OR: 2.03) as predictive risk factors of D2T RA. In conclusion, high RF levels, high DAS28-ESR, and coexisting pulmonary disease at baseline can predict the development of D2T RA.

Entities:  

Keywords:  Difficult-to-treat rheumatoid arthritis; disease activity; pulmonary involvement; rheumatoid arthritis; rheumatoid factor

Mesh:

Substances:

Year:  2021        PMID: 34033729     DOI: 10.1080/25785826.2021.1928383

Source DB:  PubMed          Journal:  Immunol Med        ISSN: 2578-5826


  2 in total

1.  Single-centre experience of refractory rheumatoid arthritis.

Authors:  John Fitton; Andrew Melville; Kamran Naraghi; Jacqueline Nam; Shouvik Dass; Paul Emery; Maya H Buch
Journal:  Rheumatol Adv Pract       Date:  2022-08-01

Review 2.  The monocyte-to-osteoclast transition in rheumatoid arthritis: Recent findings.

Authors:  Naoki Iwamoto; Atsushi Kawakami
Journal:  Front Immunol       Date:  2022-09-12       Impact factor: 8.786

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.